A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-28

Study Completion Date

2023-09-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers

NCT05837130

Parkinson Disease

COMPLETED EARLY_PHASE1

Use of a Non-Invasive Brainstem Neuromodulation Device to Improve Neurovascular Status in Parkinson's Disease

NCT04598828

Parkinson Disease

TERMINATED NA

Biomarker Analysis for GBA Associated Parkinson's Disease

NCT03811496

Parkinson Disease Gaucher Disease

UNKNOWN

Study for the Early Diagnosis of Parkinson's Disease

NCT02283073

Parkinson's Disease, Idiopathic

UNKNOWN

LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers

NCT04349865

Parkinson Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LRRK2 Mutant PD

Patients with a G2019S mutation

No interventions assigned to this group

LRRK2 Wild Type PD Low burden

Patients with a low burden of genetic modifiers

No interventions assigned to this group

LRRK2 Wild Type High burden

Patients with a high burden of genetic modifiers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female ≥40
* Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria and modified Hoehn and Yahr Stage I, II, or III;
* Willing to undergo genetic testing for neurologic genotyping panel; -If being treated for Parkinson's disease, must have been on a stable dose of anti- Parkinson's disease medications for a minimum of 30 days prior to Day 1;
* If taking statins, fibrates, antipsychotic or anticonvulsant medications at Day 1, must have been on a stable dose for a minimum of 30 days, and are not likely to require a change in dosage for the remainder of the study;

Exclusion Criteria

* Any major medical illness or unstable medical condition within 6 months of screening that, in the opinion of the Investigator or Sponsor, may interfere with the subject's ability to comply with study procedures or abide by study restrictions.
* Diagnosis of a significant central nervous system disease other than Parkinson's disease(eg, Huntington's disease, frontotemporal dementia, multi-infarct dementia, normal pressure hydrocephalus, multiple system atrophy, progressive supranuclear palsy, drug- induced parkinsonism, Alzheimer's disease)
* History of stroke;
* History of epilepsy or seizure disorder other than febrile seizures as a child, or any seizure or unexpected loss of consciousness (eg, syncope) within 6 months prior to Day 1;
* History of traumatic brain injury with residual neurological deficit; -If taking anti-Parkinson's disease medication(s)and are likely to require a change in anti- Parkinson's disease medication(s) during the study;
* Known active infectious disease or active infections within 30 days prior to Day 1;
* Any vaccination within 21 days prior to Day 1;
* Currently taking, or planning to take, anti-coagulant medications or antiplatelet medications during the study;
* Allergy to Lidocaine (xylocaine) or its derivatives or any other LP contraindications;
* Any other condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study; -Any systemic glucocorticoids taken within 14 days prior to Day 1 or non-steroidal anti- inflammatory drugs taken within 4 days prior to Day 1;
* Received blood products within 30 days prior to Day 1;
* Donated blood within 30 days prior to Day 1.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No